Logotype for Rocket Pharmaceuticals Inc

Rocket Pharmaceuticals (RCKT) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Rocket Pharmaceuticals Inc

Q3 2026 earnings summary

12 Nov, 2026

Executive summary

  • Q3 2026 net loss narrowed to $49.2M from $50.3M; nine-month net income of $26.4M included a one-time $178.2M gain from the PRV sale.

  • Priorities included advancing Danon and cardiovascular gene therapy programs and preparing KRESLADI for launch; commercial readiness was achieved October 1, with two treatment centers ready for onboarding.

Financial highlights

  • Q3 operating expenses were $51.0M versus $52.2M a year earlier; R&D was $31.2M versus $34.1M and G&A was $19.8M versus $18.4M.

  • Nine-month operating expenses fell $41.4M year over year to $146.4M; R&D declined $20.5M to $92.1M and G&A declined $17.5M to $54.3M.

  • Q3 basic and diluted loss per share were $0.43 versus $0.45; nine-month diluted EPS was $0.23 versus a $1.63 loss.

  • September 30 cash, cash equivalents and investments totaled $279.4M, versus $188.9M at December 31, 2025; total assets were $419.5M and long-term debt was $30.4M.

  • Excluding the PRV-sale gain, operating activities used $124.1M cash in the first nine months; financing provided $34.2M and investing activities provided $107.8M.

Outlook and guidance

  • Current operating plan and available cash, investments, PRV proceeds and initial debt draw are expected to fund operations into Q3 2028; conditional additional borrowing could extend runway into 2029.

  • RP-A501 pivotal-study dosing is expected to finish by mid-2027, with topline 12-month results anticipated in mid-2028.

  • R&D spending is expected to remain significant and may rise as programs advance; KRESLADI is not expected to generate material near-term revenue given its ultra-rare population and phased rollout.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Rocket Pharmaceuticals